Description
Trade name:
Haemostop
Compound:
Each tablet contains:
Etamsylate 500 mg
Excipients: lactose, sodium metabisulfite, sodium dihydrogen phosphate.
Properties:
Hemostatic agent, also has angioprotective and proaggregant effect. Stimulates the formation of platelets and their release from the bone marrow.
Indications:
Prevention and stopping of bleeding: parenchymatous and capillary bleeding (including traumatic, in surgery during operations on highly vascularized organs and tissues, during surgical interventions in dental, urological, ophthalmological, otolaryngological practice, intestinal, renal, pulmonary bleeding, metro- and menorrhagia in fibroids and others), secondary bleeding against the background of thrombocytopenia and thrombocytopathy, hypocoagulation, hematuria, intracranial hemorrhage, nosebleeds against the background of arterial hypertension, bleeding caused by taking medications.
Method of administration and dosage:
Adults: in the postoperative period – 1-2 tablets, repeated doses every 4-6 hours if the risk of bleeding persists.
To prevent and treat capillary bleeding – 1-2 tablets 3 times a day, the duration of treatment is determined by its effectiveness.
Gynecology: for menorrhagia, the drug is prescribed 5 days before the expected date of the onset of menstruation, 1-2 tablets 3 times a day for 10 days.
For children over 3 years old: 1/2 the adult dosage.
Contraindications:
Hypersensitivity to etamsylate, acute porphyria, hemoblastosis in children, thrombosis, thromboembolism; pregnancy, lactation period (breastfeeding); children under 3 years of age (for oral administration).
Precautions:
The drug is prescribed with caution in the following conditions: thrombosis, thromboembolism in the anamnesis; bleeding due to an overdose of anticoagulants; impaired liver and/or kidney function.
Side effects:
Nausea, diarrhea, heaviness in the epigastric region, skin rash, headache.
Storage method:
Store at temperatures not exceeding 30 degrees.
